<DOC>
	<DOCNO>NCT01450839</DOCNO>
	<brief_summary>This study evaluate safety tolerability E2022 16 mg tape apply repeatedly 17 day healthy elderly Japanese male subject , use E2022 placebo tape control .</brief_summary>
	<brief_title>E2022 Patch Formulation Multiple Dose Study</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria 1 . Subjects nonsmoking male ( smoke least 4 week administration investigational product Period I ) 65 year old time give informed consent 2 . Subjects whose body mass index ( BMI ) 18.5 kg/m^2 less 28.0 kg/m^2 screen 3 . Subjects give voluntary write consent participate study 4 . Subjects fully inform matter subject require observe study , willing , comply rule . Exclusion Criteria 1 . Subjects history treatmentrequiring disease within 8 week administration investigational product Period I history infection within 4 week administration investigational product Period I 2 . Subjects , within 4 week administration investigational product Period I , disease might affect evaluation investigational product , mental , gastrointestinal , hepatic , renal , respiratory , endocrine , hematological , nervous , cardiovascular disease , inborn error metabolism 3 . Subjects history surgical treatment gastrointestinal tract ( e.g. , resection liver , kidney , gastrointestinal tract , etc . ) may affect pharmacokinetics investigational product 4 . Subjects history treatmentrequiring drug food allergy seasonal allergy screen 5 . Subjects change body weight 10 % 1 day investigational product administration Period I , compare observe screen 6 . Subjects clinically significant , treatmentrequiring symptom impairment organ function , judge subjective symptoms/objective finding , vital sign , 12lead ECG , laboratory test perform period screen immediately investigational product administration Period I 7 . Subjects QTc &gt; 450 m 12lead ECG perform screen immediately investigational product administration Period I 8 . Subjects positive human immunodeficiency virus ( HIV ) antibody , hepatitis B virus surface antigen ( HBs antigen ) , hepatitis C virus ( HCV ) antibody , qualitative syphilis test , screen 9 . Subjects history , suspect diagnosis , drug alcohol dependence Subjects positive urine drug test screen 1 day investigational product administration Period I 10 . Subjects take caffeinecontaining alcoholic beverage within 72 hour investigational product administration Period I 11 . Subjects take , within 2 week investigational product administration Period I , nutritional supplement , herbcontaining drug preparation ( include Chinese medicine ) food beverage ( e.g. , grapefruitcontaining food beverage ) may affect drugmetabolizing enzyme transporter 12 . Subjects take drug preparation contain St. John 's wort within 4 week investigational product administration Period I 13 . Subjects take prescription drug within 4 week investigational product administration Period I 14 . Subjects take nonprescription drug within 2 week investigational product administration Period I 15 . Subjects participate another clinical study within 16 week investigational product administration Period I use investigational product medical device 16 . Subjects receive blood transfusion within 12 week , 400 mL whole blood collect within 12 week , 200 mL whole blood collect within 4 week , donate blood component within 2 week , investigational product administration Period I 17 . Subjects perform strenuous exercise frequency 5 day per week perform , even , strenuous exercise last 1 hour , within 2 week admission Period I 18 . Subjects past current clinical sign cutaneous hypersensitivity atopic dermatitis external medicine 19 . Subjects investigational product fix sheet apply 6 nonoverlapping site back ( except vertebral region site around angulus inferior scapula ) rotation method 20 . Subjects excessive hair application site ( back ) 21 . Subjects condition application site ( back ) , skin disease ( e.g. , eczema , dermatitis pigmentary abnormality ) , external injury , scar , may affect evaluation skin symptom 22 . Subjects , whose partner , willing take reliable contraceptive measure completion posttreatment examination 23 . Subjects judge investigator subinvestigator inappropriate subject study</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Transdermal Administration</keyword>
	<keyword>Japanese</keyword>
	<keyword>elderly</keyword>
	<keyword>male</keyword>
	<keyword>volunteer</keyword>
</DOC>